196
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

, ORCID Icon, , &
Pages 1-11 | Published online: 11 Jan 2021

References

  • Global Asthma Network. Global asthma report 2018. Available from: http://www.globalasthmareport.org/. Accessed September 24, 2020.
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
  • Global Initiative for Asthma. Global strategy for asthma management and prevention, updated 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed September 24, 2020.
  • Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042
  • Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139–1151. doi:10.1016/j.rmed.2006.03.031
  • Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861. doi:10.18553/jmcp.2016.22.7.848
  • Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J. 2010;17(2):74–80. doi:10.1155/2010/361071
  • Zeiger RS, Schatz M, Chen W, Li Q, Khatry DB, Tran TN. Adherent uncontrolled adult persistent asthma: characteristics and asthma outcomes. J Allergy Clin Immunol Pract. 2015;3(6):986–990. doi:10.1016/j.jaip.2015.06.016
  • Gerhardsson de Verdier M, Gustafson P, McCrae C, Edsbacker S, Johnston N. Seasonal and geographic variations in the incidence of asthma exacerbations in the United States. J Asthma. 2017;54(8):818–824. doi:10.1080/02770903.2016.1277538
  • Szefler SJ, Raphiou I, Zeiger RS, Stempel D, Kral K, Pascoe S. Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies. ERJ Open Res. 2019;5(2):00153–2018. doi:10.1183/23120541.00153-2018
  • DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018;39(5):345–349. doi:10.2500/aap.2018.39.4162
  • Staton TL, Arron JR, Olsson J, Holweg CTJ, Matthews JG, Choy DF. Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab. J Allergy Clin Immunol. 2017;139(5):1682–1684. doi:10.1016/j.jaci.2017.01.028
  • Johnston NW, Sears MR. Asthma exacerbations. 1: epidemiology. Thorax. 2006;61(8):722–728. doi:10.1136/thx.2005.045161
  • Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–454. doi:10.1038/nature07204
  • Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi:10.1002/14651858.CD003559.pub4
  • Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. doi:10.1002/14651858.CD010834.pub3
  • Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2018;1–10. doi:10.1080/02770903.2018.1520865
  • Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. doi:10.1056/NEJMoa1009705
  • Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
  • Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/NEJMoa1402895
  • Corren J, Parnes J, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi:10.1056/NEJMoa1704064
  • Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253–258. doi:10.1084/jem.20062211
  • Corren J, Ziegler SF. TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603–1609. doi:10.1038/s41590-019-0524-9
  • Mitchell PD, O’Byrne PM. Epithelial-derived cytokines in asthma. Chest. 2017;151(6):1338–1344. doi:10.1016/j.chest.2016.10.042
  • World Health Organization. Review of the 2014–2015 influenza season in the northern hemisphere. Available from: https://www.who.int/wer/2015/wer9023/en/. Accessed September 24, 2020.